Prostatic small cell carcinoma is an aggressive subtype of prostate cancer
that usually appears as a progression of the original adenocarcinoma, We de
scribe here the WISH-PC2, a novel neuroendocrine xenograft of small cell ca
rcinoma of the prostate. This xenograft was established from a poorly diffe
rentiated prostate adenocarcinoma and is serially transplanted in immune-co
mpromised mice where it grows within the prostate, Liver, and bone, inducin
g osteolytic lesions with foci of osteoblastic activity. It secretes to the
mouse Chromogranin A and expresses prostate plasma carcinoma tumor antigen
-1, six-transmembrane epithelial antigen of the prostate, and members of th
e Erb-B receptor family. It does not express prostate-specific antigen, pro
state stem cell antigen, prostate-specific membrane antigen, and androgen r
eceptor, and it grows independently of androgen. Altogether, WISH-PC2 provi
des an unlimited source in which to study the involvement of neuroendocrine
cells in the progression of prostatic adenocarcinoma and can serve as a no
vel model for the testing of new therapeutic strategies for prostatic small
cell carcinoma.